This suggests that ASCT may not be necessary in patients treated with intensive chemotherapy plus ponatinib.
Journal of clinical oncology:
Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias.
This most likely reflects the fact that T-ALL cases are now stratified into the high-risk arm of treatment protocols; thus, the prognostic value of del 6q depends on the treatment.
In one study, patients with T-ALL whose leukemic blast cells ectopically expressed TAL1 had an unfavorable outcome, which was thought to be due to the upregulation of antiapoptotic proteins.
The affected cells can spread into the central nervous system CNSaffecting the brain and spinal cord.
The breakpoints of some chromosomal rearrangements and gene names may have been modified from the original report for consistency and according to current HUGO gene nomenclature.
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: